Clinical Report: Healthy Participant Bias in Breast Cancer Case-Control Study
Overview
This population-based case-control study on breast cancer revealed a healthy participant bias, with controls exhibiting 34% lower overall mortality than the general population. However, similar mortality reductions in both cases and controls suggest minimal bias impact on study validity.
Background
Case-control studies assess associations between risk factors and diseases by comparing affected individuals (cases) with unaffected controls from the same population. Declining participation rates, especially among controls, raise concerns about healthy participant bias, where healthier individuals are more likely to participate, potentially skewing results. The standardized mortality ratio (SMR) is a tool to quantify this bias by comparing mortality rates of study participants to the general population. Understanding the magnitude of this bias is crucial for interpreting epidemiologic findings accurately.
Data Highlights
Group
Participation Rate (%)
SMR (Overall Mortality)
95% CI
Controls
43.4
0.66
0.62–0.69
Cases
64.1
Not specified overall; similar to controls for non-breast cancer causes
Key Findings
Participation rates were 64.1% for breast cancer cases and 43.4% for controls.
Controls had an overall mortality SMR of 0.66 (95% CI, 0.62–0.69), indicating 34% lower mortality than the general population.
For causes of death other than breast cancer, SMRs were similar between cases (0.70) and controls (0.64).
Higher education correlated with lower SMRs in both cases and controls, suggesting education as a modifier of healthy participant bias.
The healthy participant effect was present but similar in both cases and controls, reducing concern for bias in odds ratio estimates.
Clinical Implications
Clinicians and researchers should recognize that healthy participant bias can influence mortality comparisons in case-control studies, particularly among controls with lower participation rates. However, when similar bias is observed in both cases and controls, as in this breast cancer study, the validity of risk factor associations is less likely to be compromised. Adjustments for education and other sociodemographic factors may help mitigate residual bias.
Conclusion
The study demonstrates a healthy participant effect in both breast cancer cases and controls, with controls showing lower mortality than the general population. Given the similarity of this effect across groups, significant bias affecting study conclusions is unlikely.
References
MARIE Study Group 2020 -- Examining the Healthy Participant Bias in Breast Cancer Case-Control Study
